Oxford BioTherapeutics (OBT), a Calculus Capital portfolio company and leader in immuno-oncology and Antibody Drug Conjugates (ADCs), has achieved a major milestone in its collaboration with Boehringer Ingelheim. Boehringer has selected a third drug candidate from the partnership, OB33, for progression into IND-enabling studies, triggering a milestone payment to OBT.
The target was discovered using OBT’s proprietary OGAP®-Verify platform, which identifies highly specific cancer cell antigens. The latest selection highlights the platform’s increasing impact in delivering differentiated targets for therapeutic development.
As mentioned in the Times, the outlook for cancer care is shifting significantly. As noted by Professor Sir Stephen Powis, the outgoing National Medical Director of NHS England, we are “in the foothills of a treatment revolution” where cancer is becoming a manageable and increasingly curable condition thanks to breakthroughs in immunotherapy and personalised medicine.
OBT is at the forefront of this transformation, providing innovative solutions in an era where harnessing the immune system is proving critical in the fight against cancer. The OGAP®-Verify platform continues to enhance sensitivity and target validation, improving the likelihood of successful translation from lab to clinic.
Dr. Christian Rohlff, CEO of OBT, commented “This milestone reinforces the strength of our collaboration with Boehringer Ingelheim and the capabilities of our discovery platform. We are proud to contribute to the development of potentially first-in-class therapies for patients with difficult-to-treat cancers.”
This development reflects not only the scientific calibre of OBT’s team but also Calculus Capital’s commitment to supporting companies driving meaningful advances in healthcare.